NASDAQ$ABEO
Abeona Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced third quarter financial results and business progress.
Abeona Therapeutics reported its Q3 2021 financial results, with a net loss of $7.0 million. The company is advancing two late-stage pivotal assets and expects to finish patient accrual for the EB-101 Phase 3 VIITAL™ study in Q1 2022, with top-line data readout in Q3 2022.
- Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening
- Added gene therapy and biopharmaceutical industry veterans to regulatory and quality teams to prepare for two Biologics License Application (BLA) submissions
- Formally settled dispute with REGENXBIO Inc., eliminating uncertainty from arbitration outcome and facilitating planning of resources to reach next value inflection points
- Pivotal Transpher A study top-line data readout expected between Q4 2022 and Q2 2023
Headline financials
Revenue & EPS history
Abeona Therapeutics · Revenue · Quarterly
$0
Forward guidance
Abeona is focused on advancing its pipeline of therapies and preparing for BLA filings and commercial launch readiness.
Tailwinds
- Enrollment completion for Phase 3 VIITAL™ study expected in Q1 2022 with top-line data readout expected in Q3 2022
- Pivotal Transpher A study top-line data readout expected between Q4 2022 and Q2 2023
- Completed dosing seven patients at the highest dose; 2-year neurocognitive data expected in H2 2022 for efficacy evaluation
- Advancing programs toward pre-IND meetings in late-2022
- Exploring various options including strategic partnering of pipeline assets and non-dilutive funding.
Headwinds
- Potential impacts of the COVID-19 pandemic on business, operations, and financial condition
- Risks associated with data analysis and reporting
- The impact of competition
- The ability to secure licenses for any technology that may be necessary to commercialize our products
- The impact of changes in the financial markets and global economic conditions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-0.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+6.6%
Avg return
30 days after
44%
27 / 62 earnings
Positive
+18.8%
Q3 2025
Best reaction
-28.9%
Q1 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -5.5% | — | |
| Q4 2025 | +6.1% | -10.1% | +8.7% | |
| Q3 2025 | +18.8% | +8.2% | +28.5% | |
| Q1 2025 | -4.2% | -2.8% | -8.1% | |
| Q4 2024 | -1.2% | -3.8% | -6.9% | |
| Q3 2024 | -3.9% | -3.4% | -3.4% | |
| Q2 2024 | +12.7% | +13.1% | +26.5% | |
| Q1 2024 | +9.5% | +6.0% | +8.8% | |
| Q4 2023 | -12.3% | -11.8% | -8.1% | |
| Q3 2023 | +3.9% | +2.4% | +15.4% | |
| Q2 2023 | +0.7% | +0.3% | +34.6% | |
| Q1 2023 | -7.2% | -5.3% | +32.8% | |
| Q4 2022 | +1.8% | +1.8% | +10.4% | |
| Q3 2022 | -8.0% | -8.0% | -32.3% | |
| Q2 2022 | +6.5% | +14.7% | -5.8% | |
| Q1 2022 | +12.5% | +0.0% | +6.3% | |
| Q4 2021 | +3.2% | +9.7% | -32.3% | |
| Q3 2021 | -5.4% | -19.6% | -43.5% | |
| Q2 2021 | -0.8% | +3.2% | +4.8% | |
| Q1 2021 | +6.5% | +6.5% | +9.0% | |
| Q4 2020 | -1.1% | -5.8% | -14.7% | |
| Q3 2020 | +11.7% | +24.3% | +41.7% | |
| Q2 2020 | +1.7% | -3.8% | -29.0% | |
| Q1 2020 | -7.2% | +29.1% | +16.3% | |
| Q4 2019 | +17.2% | +22.4% | +43.7% | |
| Q3 2019 | -6.4% | -6.8% | +60.2% | |
| Q2 2019 | +0.0% | +6.6% | +30.7% | |
| Q1 2019 | -8.2% | -3.0% | -29.3% | |
| Q4 2018 | -2.0% | -7.2% | +1.0% | |
| Q3 2018 | -22.0% | -24.1% | -13.6% | |
| Q2 2018 | -7.1% | -11.6% | -7.1% | |
| Q1 2018 | +10.9% | +11.4% | -13.8% | |
| Q4 2017 | -9.3% | -4.7% | +17.3% | |
| Q3 2017 | +6.6% | -2.6% | +9.3% | |
| Q2 2017 | +14.9% | +5.4% | +89.2% | |
| Q1 2017 | -1.6% | -1.6% | -20.8% | |
| Q4 2016 | +2.0% | +3.0% | +13.0% | |
| Q3 2016 | +5.7% | +18.0% | -15.6% | |
| Q2 2016 | +4.3% | +5.9% | +27.1% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | -5.0% | — | — | |
| Q3 2015 | +1.8% | — | — | |
| Q2 2015 | -3.9% | — | — | |
| Q1 2015 | -7.2% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q2 2014 | -3.2% | — | — | |
| Q3 2014 | -8.5% | — | — | |
| Q1 2014 | +13.6% | — | — | |
| Q4 2013 | -10.3% | — | — | |
| Q2 2013 | -10.3% | — | — | |
| Q3 2013 | -6.3% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q4 2012 | -8.3% | — | — | |
| Q3 2012 | -7.4% | — | — | |
| Q2 2012 | +6.5% | — | — | |
| Q1 2011 | -28.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +13.9% | — | — | |
| Q2 2010 | -4.4% | — | — | |
| Q2 2011 | -4.4% | — | — | |
| Q4 2010 | -0.9% | — | — | |
| Q3 2010 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro